Topical minocycline shows promise for papulopustular rosacea in phase 2b trial

  • Webster G & al.
  • Br J Dermatol
  • 06.01.2020

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Topical minocycline gel 1% and 3% showed clinical benefit and good safety in a phase 2b trial of patients with papulopustular rosacea.

Why this matters

  • Oral minocycline has previously shown efficacy for papulopustular, but a topical may have fewer systemic adverse effects.

Key results

  • Minocycline was associated with decreased inflammatory lesions compared with vehicle:
    • 1% minocycline, P=.0147.
    • 3% minocycline, P=.0073.
  • Minocycline 3% was associated with a higher rate of success by Investigator Global Assessment (P=.0379) and reduced erythema severity score (P=.0390) compared with vehicle.
  • There were 3 treatment-related adverse events in the 1% minocycline group, 5 in the 3% minocycline group, and 1 in the vehicle group.

Study design

  • 270 patients with papulopustular rosacea and 12-40 inflammatory lesions were randomly allocated to receive minocycline 1% (n=92), minocycline 3% (n=96), or vehicle (n=82) for 12 weeks.
  • Data were analyzed for efficacy and safety outcomes.
  • Funding: Hovione Sciencia Ltd.

Limitations

  • Few endpoints analyzed.
  • Short study duration.
  • Limited safety analysis.